List of Excipients in Branded Drug ACCOLATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Par Pharmaceutical Inc	ACCOLATE	zafirlukast	49884-589	CELLULOSE, MICROCRYSTALLINE
Par Pharmaceutical Inc	ACCOLATE	zafirlukast	49884-589	CROSCARMELLOSE SODIUM
Par Pharmaceutical Inc	ACCOLATE	zafirlukast	49884-589	HYPROMELLOSES
Par Pharmaceutical Inc	ACCOLATE	zafirlukast	49884-589	LACTOSE
Par Pharmaceutical Inc	ACCOLATE	zafirlukast	49884-589	MAGNESIUM STEARATE
Par Pharmaceutical Inc	ACCOLATE	zafirlukast	49884-589	POVIDONE
Par Pharmaceutical Inc	ACCOLATE	zafirlukast	49884-589	TITANIUM DIOXIDE

Accolate (Zafirlukast) Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Accolate, the brand name for zafirlukast, is an aging leukotriene receptor antagonist with limited brand value but several formulation opportunities. The commercial opportunity is primarily in generic differentiation, pediatric delivery, lactose-free reformulation, improved swallowability, and dependable supply of excipients. Patent exclusivity is no longer a meaningful barrier in the United States, and zafirlukast has no biosimilar pathway because it is a small-molecule drug.

What is Accolate and how is zafirlukast supplied?

Accolate contains zafirlukast, an orally active cysteinyl leukotriene receptor antagonist approved for the prophylaxis and chronic treatment of asthma. The original product was supplied as film-coated tablets in 10 mg and 20 mg strengths. Zafirlukast is generally administered twice daily on an empty stomach because food can reduce systemic exposure.[1]

Attribute	Accolate / zafirlukast
Active ingredient	Zafirlukast
Drug class	Leukotriene receptor antagonist
Original sponsor	AstraZeneca
FDA approval	1996
Dosage form	Film-coated immediate-release tablet
Strengths	10 mg and 20 mg
Primary use	Chronic asthma prophylaxis
U.S. regulatory pathway	NDA for Accolate; ANDAs for generic zafirlukast
Biologic status	Small molecule; no biosimilar pathway
Current exclusivity position	Expired
Key administration issue	Take at least one hour before or two hours after meals
Main formulation constraint	Food effect, low-dose drug loading, taste and swallowability

Zafirlukast has a relatively low daily dose compared with many oral drugs. That creates a high excipient-to-active ratio, making blend uniformity, segregation control, tablet weight variation and content uniformity important development issues.

What excipients are used in Accolate tablets?

The Accolate formulation uses conventional tablet excipients for dilution, binding, disintegration, lubrication and film coating. The U.S. prescribing information identifies lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone and magnesium stearate in the tablet core, with conventional film-coating components.[1]

Functional role	Accolate excipient class	Formulation purpose
Filler	Lactose monohydrate	Adds bulk and supports tablet compression
Filler and compression aid	Microcrystalline cellulose	Improves compactibility and tablet strength
Superdisintegrant	Croscarmellose sodium	Promotes rapid tablet breakup
Binder	Povidone	Improves granule and tablet cohesion
Lubricant	Magnesium stearate	Reduces die-wall friction and ejection force
Film coating	Hypromellose-based coating system	Protects the tablet and improves appearance and swallowing
Opacifier or colorant	Titanium dioxide and other conventional coating components, depending on market presentation	Product identification and light protection

The commercial significance of this composition is limited. These excipients are widely available and generally nonproprietary. The opportunity lies in selecting substitute excipients that improve manufacturing economics or create differentiated dosage forms, not in reproducing the original composition exactly.

How should a generic manufacturer approach the Accolate excipient strategy?

A conventional immediate-release tablet remains the lowest-risk route. The formulation should first target bioequivalence with the reference product, then optimize manufacturing robustness and market-specific attributes.

Immediate-release tablet strategy

A generic developer can evaluate:

• Lactose-free fillers such as anhydrous dibasic calcium phosphate, mannitol, starch-based fillers or additional microcrystalline cellulose.
• Co-processed excipients to improve direct compression and reduce granulation steps.
• Alternative superdisintegrants such as sodium starch glycolate or crospovidone.
• Lower-magnesium-stearate systems to reduce hydrophobic coating of particles and improve dissolution.
• Film coatings with lower titanium dioxide content or titanium-dioxide-free pigments.
• Hypromellose or polyvinyl alcohol coating systems for improved mechanical protection.

The principal development target is rapid and reproducible dissolution without changing the food-related exposure profile. An apparently faster-dissolving formulation may still require careful pharmacokinetic evaluation because zafirlukast exposure is affected by food and gastrointestinal conditions.

Wet granulation versus direct compression

Direct compression can reduce equipment, labor and process time. It may be attractive when the selected grade of microcrystalline cellulose or a co-processed filler provides adequate flow and compactibility.

Wet granulation may be preferable when the formulation has poor flow, segregation risk or unacceptable tablet-weight variability. Zafirlukast’s relatively low dose makes segregation control important, particularly in the 10 mg strength. Granulation can improve content uniformity but adds drying, residual-moisture and scale-up variables.

Development route	Advantages	Principal risk
Direct compression	Lower processing cost; simpler manufacturing	Segregation and poor flow at low drug loading
Wet granulation	Better blend uniformity and flow	Moisture exposure, longer cycle time and possible stability impact
Dry granulation	No aqueous exposure; scalable	Potential loss of compactibility and higher tablet friability
Co-processed excipient system	Simplified formulation and improved manufacturability	Supplier dependence and excipient-specific regulatory documentation

What formulations are protected or commercially available for zafirlukast?

The marketed Accolate dosage form is an immediate-release film-coated tablet. There is no strong commercial evidence that a proprietary Accolate formulation patent remains relevant to current U.S. entry. The original zafirlukast compound and product exclusivities expired years ago, and the FDA Orange Book is the relevant source for any current listed patents or exclusivity entries.[2]

Potential differentiated formulations include:

1. Lactose-free tablets. This is the most straightforward excipient-led opportunity for patients with lactose intolerance, dietary restrictions or intolerance to the reference formulation.
2. Small, high-strength tablets. A smaller 20 mg tablet could improve swallowability and reduce packaging volume.
3. Orally disintegrating tablets. An ODT could address swallowing difficulty, although taste masking and rapid dissolution would require careful development.
4. Pediatric granules or mini-tablets. Zafirlukast is approved for pediatric use in certain age groups, but a flexible pediatric dosage form could improve administration.
5. Sprinkle or dispersible systems. These could support administration to children or patients unable to swallow tablets, subject to food-effect and bioequivalence considerations.
6. Low-allergen formulations. The product can be positioned without lactose, selected colorants or other excipients that create market-access restrictions.
7. Unit-dose packaging. Blister packaging can improve adherence, protect tablets from humidity and support institutional distribution.

A new dosage form may require more than a routine ANDA strategy. Depending on the formulation and labeling changes, the sponsor may need a suitability petition, a 505(b)(2) application or a new ANDA supported by comparative bioequivalence data.[3]

When does Accolate lose exclusivity?

Accolate lost U.S. market exclusivity long ago. The product received FDA approval in 1996, and the relevant small-molecule patent and regulatory exclusivity periods have expired. Current commercial entry therefore depends on ANDA approval, product quality, manufacturing cost, supply reliability and contracting rather than on overcoming an active innovator patent barrier.

Exclusivity category	Current position
New chemical entity exclusivity	Expired
Original compound patents	Expired
Pediatric exclusivity	Expired, if previously granted
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Orange Book patent barrier	No material current barrier expected based on the mature product history
Generic entry route	ANDA, subject to applicable FDA requirements

Patent status must still be checked against the current Orange Book and FDA approval records before filing. Historical patents should not be treated as active barriers based solely on their original filing dates.[2]

What is the FDA regulatory status of Accolate and generic zafirlukast?

The branded Accolate product is a mature FDA-approved product. The commercial market is primarily relevant to generic zafirlukast tablets. FDA approval requires demonstration that the generic has the same active ingredient, strength, dosage form, route of administration and applicable quality characteristics as the reference product.[3]

The major regulatory issues are:

• Comparative bioavailability and bioequivalence.
• Dissolution performance across pH conditions.
• Content uniformity at the 10 mg strength.
• Control of degradation products.
• Food-effect implications.
• Tablet stability under humidity and temperature stress.
• Justification for any inactive-ingredient differences.
• Label consistency regarding fasting administration.
• Manufacturing-site inspection readiness.

Zafirlukast is metabolized primarily through hepatic pathways, including CYP2C9-related metabolism, and has clinically relevant hepatic safety considerations. The excipient system should not introduce a new interaction concern or materially change absorption in a way that complicates labeling.[1]

What generic entry risks exist for zafirlukast?

The legal risk is low compared with newer branded medicines, but technical and commercial risks remain.

Bioequivalence risk

Changing fillers, disintegrants or coating systems can alter dissolution and absorption. This risk is greater for a low-dose drug with a relatively high excipient load. A formulation that passes routine dissolution may still produce unacceptable pharmacokinetic variability.

Food-effect risk

The label requires administration away from meals. A new formulation should not create a materially different food effect unless the sponsor is willing to support new clinical pharmacology work and potentially revise the product strategy.

Pediatric-use risk

A pediatric dosage form can create commercial value, but it also introduces taste, dose flexibility, dosing-device and caregiver-use requirements. Granules or mini-tablets may be more practical than an ODT if the target population includes younger children.

Manufacturing risk

Magnesium stearate concentration and blending time can materially affect dissolution. Over-lubrication is a common risk in immediate-release tablets. Moisture-sensitive excipients or high-residual-moisture granulation can affect stability.

Market risk

Zafirlukast competes with inhaled corticosteroids, leukotriene receptor antagonists such as montelukast and other controller therapies. Montelukast has stronger brand recognition and once-daily administration. A zafirlukast product therefore needs a clear cost, supply, formulation or patient-access advantage.

Which excipient-led commercial opportunities are most attractive?

1. Lactose-free generic zafirlukast

A lactose-free formulation is the lowest-complexity differentiation strategy. It can use established excipients, preserve the immediate-release tablet format and support a clean-label positioning. The commercial benefit depends on payer coverage and the size of the target patient population.

2. Pediatric mini-tablets or granules

Pediatric delivery has stronger differentiation potential than a simple filler substitution. A 5 mg mini-tablet, multiparticulate product or measured granule presentation could improve dosing flexibility. The principal barrier is taste masking because zafirlukast is not naturally suited to an unflavored oral powder.

3. ODT or dispersible tablet

An ODT could address swallowing limitations and create a differentiated product under a 505(b)(2) strategy. Commercial success would require effective taste masking without slowing disintegration or altering the food-related pharmacokinetic profile.

4. Supply-chain and cost optimization

A manufacturer can generate value without a new dosage form by qualifying dual sources for lactose, microcrystalline cellulose, croscarmellose sodium, povidone and coating materials. For a low-price generic, supply continuity and lower conversion cost may be more valuable than premium formulation positioning.

5. Titanium-dioxide-free coating

A coating system that avoids titanium dioxide may support regulatory and procurement requirements in selected jurisdictions. It is unlikely to create significant standalone pricing power, but it can simplify international portfolio management.

Opportunity	Development complexity	Differentiation	Commercial attractiveness
Conventional generic tablet	Low to moderate	Low	Moderate
Lactose-free tablet	Moderate	Moderate	Moderate
Smaller tablet	Moderate	Moderate	Moderate
Pediatric mini-tablet	Moderate to high	High	Selective
Oral granules	High	High	Selective
ODT	High	High	Selective
Dual-source excipient platform	Low	Low	High for cost control

How strong is the patent estate for Accolate?

The current patent estate is weak from a generic-entry perspective because Accolate is a 1990s small-molecule product with expired compound and regulatory exclusivity. The relevant competitive barriers are formulation execution, manufacturing economics and market demand.

A new excipient combination could receive patent protection only if it produces a non-obvious technical effect, such as a demonstrated improvement in stability, dissolution, bioavailability, taste masking or dose uniformity. Routine substitution of lactose, microcrystalline cellulose or croscarmellose sodium would generally provide limited patent strength.

A stronger formulation patent would require:

• Defined quantitative excipient ranges.
• Comparative data against the reference formulation.
• A measurable technical benefit.
• Reproducible performance across manufacturing scale.
• Claims directed to a specific dosage form or process.
• Support for stability, dissolution and pharmacokinetic advantages.

Geographic protection would need to be evaluated separately in the United States, Europe, Japan and other markets. Expired U.S. compound protection does not establish freedom to operate for a new formulation in every jurisdiction.

What patent litigation and settlement issues affect zafirlukast?

No major current U.S. patent litigation appears to define the zafirlukast market. Historical generic challenges, if any, are unlikely to create a current market barrier because the core exclusivity period has ended. Settlement agreements would matter only if they contained surviving supply, licensing, manufacturing or launch restrictions, which should be reviewed in transaction diligence.

The relevant legal workstream is therefore prospective:

• Search current Orange Book listings for the reference NDA.
• Review active formulation or process patents filed after the original product launch.
• Check pending Paragraph IV certifications and ANDA litigation dockets.
• Review FDA patents and exclusivity records before filing.
• Assess foreign national-phase patents for differentiated products.
• Confirm that any new coating, granulation or pediatric dosage form does not infringe third-party technology.

How does zafirlukast compare with montelukast for formulation opportunities?

Montelukast is commercially stronger because of broader physician recognition, once-daily dosing and greater historical market penetration. Zafirlukast has a more limited opportunity but may offer a simpler formulation and lower competitive intensity in selected generic channels.

Factor	Zafirlukast	Montelukast
Main dosage frequency	Twice daily	Once daily
Food restriction	Important; administer away from meals	Formulation- and label-dependent
Established dosage forms	Tablets	Tablets, chewables, granules and other presentations
Pediatric opportunity	Underdeveloped relative to montelukast	More commercially established
Patent barrier today	Low	Low for core generic products, but product-specific rights must be checked
Excipient differentiation	Lactose-free, pediatric, ODT and supply optimization	Taste masking, chewables, granules and pediatric formats
Commercial demand	Niche and price-sensitive	Larger and more competitive

Zafirlukast’s food restriction is a commercial disadvantage. A formulation that improves adherence without changing exposure could provide more value than a minor tablet-size reduction.

What is the likely revenue exposure and launch outlook?

Revenue exposure is limited for the branded product but can be meaningful for a low-cost generic manufacturer with efficient production and broad distribution. The market is unlikely to support substantial premium pricing without a differentiated pediatric or adherence-oriented presentation.

A generic launch scenario can be assessed as follows:

Launch scenario	Expected market position	Main value driver
Standard 10 mg and 20 mg tablets	Commodity generic	Low manufacturing cost
Lactose-free product	Differentiated generic	Patient and formulary preference
Pediatric mini-tablet	Specialty generic	Dose flexibility and administration
Granule or dispersible product	Specialty or 505(b)(2) product	Swallowability and pediatric use
Dual-source formulation	Contract and institutional supply	Reliability and margin protection

Key Takeaways

• Accolate is zafirlukast, a mature small-molecule asthma drug approved by the FDA in 1996.
• Its original patent and regulatory exclusivity periods have expired.
• The commercial market is primarily generic and price-sensitive.
• The original formulation uses conventional excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone and magnesium stearate.
• The strongest near-term excipient opportunity is a lactose-free, manufacturing-optimized immediate-release tablet.
• Pediatric mini-tablets, granules and ODTs offer greater differentiation but carry higher bioequivalence, taste and regulatory risk.
• Food-effect control, low-dose content uniformity and over-lubrication are central technical issues.
• Zafirlukast has no biosimilar pathway because it is not a biologic.
• New excipient patents would require data showing a non-obvious technical improvement rather than routine ingredient substitution.
• A final filing and freedom-to-operate assessment should rely on current FDA Orange Book and patent records.

FAQs About Accolate Excipient Strategy

Can zafirlukast tablets be made without lactose?

Yes. Lactose can be replaced with suitable fillers such as microcrystalline cellulose, mannitol, dibasic calcium phosphate or co-processed excipients, subject to formulation development and bioequivalence requirements.

Is an Accolate oral suspension commercially attractive?

Potentially, but an oral suspension would require control of dose uniformity, sedimentation, redispersibility, taste, preservative compatibility and stability. It would likely require a more complex regulatory strategy than a conventional generic tablet.

Can zafirlukast be formulated as a chewable tablet?

A chewable product is technically possible, but taste masking is a central barrier. The sponsor would need to establish acceptable palatability while preserving dissolution and systemic exposure.

Does zafirlukast have biosimilar competition?

No. Zafirlukast is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, not the FDA biosimilar pathway.

Which excipient is most important for zafirlukast dissolution?

The combined effect of the disintegrant, binder, lubricant and compression process is more important than any single excipient. Croscarmellose sodium and magnesium stearate levels, blending time and tablet hardness should receive particular attention.

References

1. U.S. Food and Drug Administration. (1996). Accolate (zafirlukast) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Approved drug products and abbreviated new drug application requirements.
4. National Library of Medicine. (n.d.). Zafirlukast drug label information. DailyMed.
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.